Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Head and Neck Neoplasms 2Xerostomia 1Thyroid Carcinoma, Anaplastic 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neutropenia 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1

Interventions

Temozolomide 2Filgrastim 2Everolimus 2trifluridine tipiracil drug combination 1sargramostim 1poly ICLC 1pegfilgrastim 1pasireotide 1gadobutrol 1gadobenic acid 1dactolisib 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Vaccines 1Topotecan 1Surgical Procedures, Operative 1Radiotherapy 1O(6)-benzylguanine 1Methylphenidate 1Magnetic Resonance Spectroscopy 1Genistein 1Gadolinium DTPA 1Decitabine 1Cyclophosphamide 1Congresses as Topic 1Carmustine 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroectodermal Tumors, Primitive × pegfilgrastim × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡